1. Home
  2. ENLV

as of 03-20-2026 3:58pm EST

$1.03
$0.06
-5.09%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Founded: 2005 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 258.7M IPO Year: 2014
Target Price: $13.00 AVG Volume (30 days): 199.5K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.66 - $2.10 Next Earning Date: 04-29-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered ENLV Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 21 hours ago

AI Recommendation

hold
Model Accuracy: 75.47%
75.47%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: